Cogent Biosciences, Inc. (COGT) Stock Price, Financials & Summary

Price chart

Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18

Key dataSep 18, 2026

Open$33.21

From 52W high−26.47%

Volume4.55M

Market cap$5.47B

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataSep 18, 2026

Open

$33.21

From 52W high

−26.47%

Volume

4.55M

Market cap

$5.47B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−13.4x

P/E (TTM)

—

RSI (14)

30.2

MomentumView details →

1D Return

−5.09%

YTD Return

−11.32%

SummaryUpdated Jun 1, 2026

Cogent Biosciences, Inc. (NASDAQ:COGT) is a biotechnology company founded in 2014 and headquartered in Cambridge, Massachusetts. Originally incorporated as Unum Therapeutics Inc., the company underwent a strategic transformation and rebranded to Cogent Biosciences in October 2020. The company went public in March 2018 and focuses on developing precision therapies for genetically defined diseases, particularly targeting rare conditions with significant unmet medical needs.

Ask drillr about Cogent Biosciences, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−13.4x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

10.3x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−70.85%

ROA (TTM)

−45.20%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+4.55%

FCF YoY

−31.79%

Revenue CAGR 3Y

—

EPS CAGR 3Y

+12.07%

EBITDA YoY

−28.64%

MomentumView details →

1D Return

−5.09%

YTD Return

−11.32%

1Y Return

+163.16%

RSI (14)

30.2

vs 50D SMA

−15.87%

vs 200D SMA

−14.32%

Capital & dividendView details →

Debt/Equity

0.46x

Current Ratio

13.57x

Quick Ratio

13.57x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.52

EPS Surprise

6.30%

Beats (12Q)

3/12

Next Q EPS Est

−$0.56

Avg Surprise (4Q)

1.47%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−377.18M

Op. CF (TTM)

−307.55M

Next earningsNov 6, 2026 →

Latest newsMore news →

The FDA accepted Cogent Biosciences' New Drug Application for bezuclastinib in patients with advanced systemic mastocytosis, supported by positive results from the APEX pivotal trial.5d ago

Cogent Biosciences signed a five-year commercial supply agreement with Hovione FarmaCiencia S.A. for the purchase of bezuclastinib spray-dried dispersion and tablets, with automatic two-year renewals.18d ago

Similar companies

CRISPR Therapeutics AGCRSP PTC Therapeutics, Inc.PTCT Dianthus Therapeutics, Inc.DNTH CK Life Sciences Int'l., (Holdings) Inc.00775.HK Ligand Pharmaceuticals IncorporatedLGND Scholar Rock Holding CorporationSRRK Find similar companies →

Latest newsMore news →

The FDA accepted Cogent Biosciences' New Drug Application for bezuclastinib in patients with advanced systemic mastocytosis, supported by positive results from the APEX pivotal trial.5d ago Cogent Biosciences signed a five-year commercial supply agreement with Hovione FarmaCiencia S.A. for the purchase of bezuclastinib spray-dried dispersion and tablets, with automatic two-year renewals.18d ago Cogent Biosciences reported a net loss of $96.4 million for Q2 2026, with research and development expenses of $70.8 million and general and administrative expenses of $31.8 million.42d ago